TB500 5mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

TB-500 is a lab-made peptide fragment that copies the active region (the sequence Ac-LKKTETQ) of Thymosin Beta-4, a naturally occurring 43-amino-acid protein tied to cell movement and tissue repair[1][5]. This educational page outlines a once-daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. It is an unapproved research chemical, not a medicine, and there are no completed human efficacy trials of the TB-500 fragment itself — presented for research and educational use only.

Add 3.0 mL bacteriostatic water to one 5 mg vial → ~1.67 mg/mL (1,667 mcg/mL), the largest practical dilution for accurate dosing.
500–1000 mcg once daily, titrated upward gradually across an 8–12 week course (about ~5 mg per week on average).
At ~1.67 mg/mL, 1 unit ≈ 16.7 mcg; 500 mcg ≈ 30 units and 1000 mcg ≈ 60 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard / Gradual Approach (3 mL = ~1.67 mg/mL)

Phase / Week(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	500 mcg (1× daily)	~30 units (0.30 mL)
Weeks 3–4	600 mcg (1× daily)	~36 units (0.36 mL)
Weeks 5–8	750 mcg (1× daily)	~45 units (0.45 mL)
Weeks 9–12	1000 mcg (1× daily)	~60 units (0.60 mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 5 mg vial → final concentration ~1.67 mg/mL (1,667 mcg/mL).
Typical daily range: 500–1000 mcg once daily, raised gradually over an 8–12 week course.
Easy measuring: At ~1.67 mg/mL, 1 unit ≈ 16.7 mcg on a U-100 syringe. Using the large 3.0 mL dilution keeps every dose at 30 units or more for excellent measuring accuracy.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Frequency: one subcutaneous injection each day, titrating up as tolerated. Across the cycle the weekly total averages roughly 5 mg, in line with commonly cited research schedules[3][4]. These figures come from reference protocols, not from approved human dosing.

Reconstitution Steps

Draw 3.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution is deliberately large so each dose reads at 30 units or more, where U-100 syringe markings are most precise. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume an 8–16 week course of once-daily injections with gradual titration.

A 5 mg vial is roughly one week of dosing at the ~5 mg/week average, so plan about one vial per week.
8 weeks: ~8 vials
12 weeks: ~12 vials
16 weeks: ~16 vials
Per injection: 1 syringe
8 weeks (once daily): ~56 syringes
16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 5 mg vial for reconstitution.
8 weeks (8 vials): ~24 mL → 3 bottles
16 weeks (16 vials): ~48 mL → 5 bottles
One for the vial stopper + one for the injection site each day.
Per injection: 2 swabs
8 weeks (once daily): ~112 swabs → 1–2 boxes

Protocol Overview

A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.

▪Goal: Support tissue repair, wound healing and angiogenesis via the active Thymosin Beta-4 fragment — effects reported preclinically, not established in humans[5][6].
▪Schedule: Daily subcutaneous injections for 8–12 weeks, optionally extended to ~16 weeks for longer research goals.
▪Dose Range: 500–1000 mcg per day with gradual titration, averaging about ~5 mg per week.
▪Reconstitution: 3.0 mL bacteriostatic water per 5 mg vial gives ~1.67 mg/mL for accurate unit measurements.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A suggested daily titration approach based on common reference doses.

▪Start: Begin at 500 mcg once daily to gauge tolerability.
▪Titrate: Increase by roughly 100–150 mcg every two weeks as tolerated.
▪Target: Reach about 750–1000 mcg daily by weeks 5–12.
▪Cycle Length: Typically 8–12 weeks; some references extend to ~16 weeks.
▪Timing: Inject at a consistent time each day and rotate injection sites systematically.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep daily administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
▪Regulatory note: TB-500 is prohibited by WADA for athletic use and is not FDA-approved for human administration[10].

How This Works

TB-500 is a synthetic fragment that reproduces the active N-terminal region of Thymosin Beta-4 (Tβ4) — specifically the short sequence Ac-LKKTETQ[1][2]. That region carries the actin-binding activity of the full protein.

Its core proposed mechanism is the sequestering of G-actin, which helps regulate actin polymerization — the process behind the cell migration that is central to wound healing. In preclinical work the fragment has also been linked to angiogenesis (new blood-vessel growth, including VEGF signalling), recruitment of stem and progenitor cells, and reduced inflammation and fibrosis[5][6].
Animal studies have described greater collagen deposition and shorter healing times at injury sites treated with thymosin fragments[11], and some metabolic work suggests TB-500 may behave as a prodrug that cleaves to a shorter active metabolite[12].
Important caveat: there are no completed human efficacy trials of the TB-500 fragment itself. The limited human data involve full-length Thymosin Beta-4 — a different, larger molecule, studied mainly as an eye-drop — not this peptide. Musculoskeletal “recovery” and “healing” claims rest on animal data and anecdote, and should be read as hypotheses.
TB-500 is not an approved medicine. It is an unapproved research chemical presented here for research and educational purposes only.

Lifestyle Factors

Habits that may support recovery alongside the protocol.

▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs.
▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase.
▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
▪Stress: Manage stress with evidence-based practices, since it influences overall healing.

Potential Benefits & Side Effects

What preclinical and veterinary literature describe; human evidence is limited and individual results vary.

▪Wound healing (preclinical): Animal studies report faster wound healing and tissue repair via enhanced angiogenesis and cell migration[5][6].
▪Inflammation & fibrosis (preclinical): Thymosin pathways have been linked to reduced inflammation and fibrosis in animal models[11].
▪Tolerability (veterinary): Generally well tolerated in veterinary studies, with occasional mild injection-site reactions.
▪Note on humans: These benefits are not established in humans — no large-scale clinical trials of the TB-500 fragment have been completed[13].
▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
▪Sport restriction: Note that TB-500 is a WADA-prohibited substance for athletes.

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[14][15].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
▪Draw the intended dose, then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for TB-500 (5 mg).

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for TB500 5mg.

TB-500 (5mg Vial) Dosage Protocol Open source
1 FASEB Journal Biological activities of thymosin beta-4 mapped to active peptide sequences, including the fragment marketed as TB-500. View Source ↗ Open source
2 Journal of Chromatography A (PubMed) Doping-control analysis of TB-500 as a synthetic thymosin beta-4 fragment in biological samples. View Source ↗ Open source
3 WADA Scientific Research Investigation of TB-500 metabolism, synthesis of its metabolites, and detection limits. View Source ↗ Open source
4 Racing Medication & Testing Consortium Thymosin beta-4 regulatory bulletin covering TB-500 use in equine sports medicine. View Source ↗ Open source
5 Journal of Investigative Dermatology (PubMed) Thymosin beta-4 accelerates wound healing in a preclinical model. View Source ↗ Open source
6 FASEB Journal (PubMed) Active-site mapping of thymosin beta-4 fragments for angiogenesis and cell migration. View Source ↗ Open source
7 Peptide Storage Guide Best practices for storing lyophilized peptides (temperature, humidity and light protection). View Source ↗ Open source
8 Bacteriostatic Water Guidance Bacteriostatic water for injection: multi-dose vial stability and handling. View Source ↗ Open source
9 NCBI Bookshelf Best practices for subcutaneous injection: aseptic technique and site rotation. View Source ↗ Open source
10 WADA Prohibited List Classification of TB-500 as a prohibited substance in competitive sport. View Source ↗ Open source
11 Journal of Investigative Dermatology Thymosin beta-4 wound-healing mechanisms: collagen deposition, angiogenesis and granulation tissue. View Source ↗ Open source
12 Journal of Chromatography B (PubMed) Quantification of TB-500 metabolites and screening of wound-healing activity (prodrug hypothesis). View Source ↗ Open source
13 ClinicalTrials.gov Trial registry for full-length thymosin beta-4 (e.g., dermal and ocular indications); no completed efficacy trials of the TB-500 fragment. View Source ↗ Open source
14 Centers for Disease Control and Prevention (CDC) Subcutaneous injection technique: angle, site and no-aspiration guidance. View Source ↗ Open source
15 Subcutaneous Injection Technique (Patient Education) How to administer a subcutaneous injection: clinical technique guidelines. View Source ↗ Open source
16 Prime Lab Peptides TB-500 (5 mg) product page — purity specifications and certificates of analysis. View Source ↗ Open source

Contents